TO THE EDITOR
Philadelphia (Ph)-chromosome-positive chronic myeloid leukemia (CML) with the e19a2 rearrangement encoding p230 protein is a rare disease with varying clinical presentation and course. [1] [2] [3] [4] [5] The e19a2 rearrangement was initially reported to be present as neutrophilic CML with a benign clinical course, but it has been reported with increasing frequency in patients with typical CML, and some of these patients exhibit an aggressive clinical course. [1] [2] [3] [4] [5] Although several therapeutic modalities have been attempted, there is no consistent data on the treatment of CML patients with the e19a2 rearrangement. [1] [2] [3] [4] [5] Since imatinib (Glivec s ) induces a substantial cytogenetic response in chronic-phase (CP) CML after a-interferon failure, imatinib is used in all phases of CML at present. 6 However, most of the patients reported in previous studies were CML with p210 or p190 protein.
Here, we describe three Ph-positive CML patients with the e19a2 rearrangement, in whom the BCR-ABL transcript responded to imatinib rapidly, based on real-time quantitative reverse transcriptase-polymerase chain reaction (Q-RT-PCR) analysis ( Table 1) .
The first patient was a 23-year-old woman with a CML myeloid blast crisis (BC), who had 169 Â 10 9 white blood cells (WBC)/l with 26% blasts, 7% promyelocytes, and 18% myelocytes, and a huge spleen that was palpable 25 cm below the costal margin. She was initially treated with 600 mg imatinib a day. The second patient was a 47-year-old man with CP CML and 32.1 Â 10 9 WBC/l with 80% neutrophils, 15% lymphocytes, 1% monocytes, 2% eosinophils, and 2% basophils, and no organomegaly. He was refractory to initial a-interferon treatment and was subsequently started on 400 mg imatinib a day. The third patient was a 55-year-old man with CP CML and 17 Â 10 9 WBC/l with 72% neutrophils, 15% lymphocytes, 10% monocytes, 1% eosinophils, and 2% basophils, and a huge spleen that was palpable 15 cm below the costal margin. He was refractory to initial a-interferon treatment and was subsequently started on 400 mg imatinib a day.
The cytogenetics and interphase fluorescence in situ hybridization (FISH) were performed on BM specimens as described previously, 7 and at least 500 nuclei were counted for hybridization signals. The two-step nested RT-PCR was carried out as reported previously, 7 and sequencing analysis finally confirmed that the PCR product was derived from the fusion of BCR exon 19 and ABL exon 2 (e19a2). The Q-RT-PCR was also carried out as reported previously. 7 After imatinib treatment, all three patients achieved a complete cytogenetic response (CCR) at 6 months. On FISH analysis, the initial value for all three patients averaged 50%, but after 6 months it averaged 2-3%. All patients showed a marked reduction of BCR-ABL transcript beginning 3 months after imatinib treatment. In addition, the BCR-ABL/ABL continuously decreased below 1% during treatment. In detail, the first patient had a partial cytogenetic response with a reduction of the BCR-ABL transcripts at 3 months and achieved a CCR at 6 months. Then, she underwent allogeneic bone marrow transplantation (BMT) from an HLA-identical unrelated donor at 9 months, resulting in no detection of transcript by Q-RT-PCR analysis but weakly positive result in second-round RT-PCR. The second and third achieved a CCR at 6 months only with imatinib treatment. The third patient developed cytopenia during early period of treatment and imatinib was stopped. After he recovered, he was restarted on 400 mg imatinib per day and showed a reduction in the level of transcript. Our patients showed a rapid response during early period of imatinib treatment, as seen in CML with p210 and p190.
CML with e19a2 transcript was initially identified due to a discrepancy between Ph-positive cytogenetic findings and Southern blots showing no rearrangement of M-BCR. 5 A better approach to identify unusual BCR-ABL transcripts is an application of multiplex PCR, which is a highly specific PCR with low sensitivity and a clear advantage for screening potential CML patients. 8 In early reports, patients with the e19a2 rearrangement were described as having neutrophilic CML, which is characterized by a more benign clinical course than classical CML.
1,2 Subsequently, there were several reports of the e19a2 rearrangement in patients with classical CML with various clinical outcomes, from a chronic course to an aggressive clinical course. 3, 4 The therapeutic modalities used in CML patients with e19a2 transcript vary. In the 1990s, most patients were treated with hydroxyurea, busulfan, interferon, or a combination thereof, with various clinical outcomes.
1-4 Polak et al 5 reported a case of accelerated-phase (AP) CML with e19a2 transcript that was successfully treated with allogeneic BMT.
In our study, all the patients showed an aggressive clinical course before they were treated with imatinib. In the case with the BC CML, the imatinib served as a bridge to a successful allogeneic BMT. In other two CML patients who failed to respond to interferon, the imatinib served as a salvage treatment.
In conclusion, these findings indicate that imatinib is also effective in the treatment of CML with e19a2 transcript encoding p230 protein. Further experience with imatinib treatment in this CML subtype is necessary because of the low incidence of CML with e19a2 transcript. 
